L. Michel

发表

Stereotactic radiosurgery for brain metastases from pelvic gynecological malignancies: oncologic outcomes, validation of prognostic scores, and dosimetric evaluation

A. Schneeweiss, J. Debus, L. König, 2021, International Journal of Gynecological Cancer.

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases

D. Jäger, F. Marmé, Michael Thomas, 2020, Neuro-oncology advances.

Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?

A. Schneeweiss, M. Golatta, C. Sohn, 2020, Cancers.

Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS+EG score

A. Schneeweiss, M. Golatta, C. Sohn, 2019, Senologie - Zeitschrift für Mammadiagnostik und -therapie.

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

M. Lux, M. Beckmann, P. Fasching, 2020, Cancers.

Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer

L. Uhlmann, A. Schneeweiss, M. Golatta, 2022, Archives of Gynecology and Obstetrics.

Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer

A. Schneeweiss, B. Burwinkel, A. Turchinovich, 2022, Archives of Gynecology and Obstetrics.

Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast

P. Fasching, A. Schneeweiss, C. Denkert, 2021, European Journal of Cancer.

Age-Dependent Hematologic Toxicity Profiles and Prognostic Serologic Markers in Postoperative Radiochemotherapy Treatment for Uterine Cervical Cancer

A. Schneeweiss, J. Debus, P. Hoegen, 2022, Technology in cancer research & treatment.

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

C. Denkert, F. Marmé, S. Loibl, 2022, Breast.

Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, European journal of cancer.

Return of individual genomic research results within the PRAEGNANT multicenter registry study

M. Lux, M. Beckmann, L. Häberle, 2022, Breast Cancer Research and Treatment.

Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer

A. Schneeweiss, F. Schütz, A. von Au, 2020, Targeted Oncology.

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, The Lancet. Oncology.

The Prognostic Benefit of Early Postoperative Radiotherapy and Diagnostic Value of Serologic Markers on Women with Uterine Sarcoma and Carcinosarcoma

A. Schneeweiss, J. Debus, P. Hoegen, 2022, Journal of Oncology Research and Therapy.

1552O Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial

A. Schneeweiss, M. Weiler, F. Marmé, 2022, Annals of Oncology.

Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs

A. Trumpp, W. Wick, M. Preusser, 2020, Molecular Cancer Research.

Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index

Michael Golatta, Andreas Schneeweiss, André Hennigs, 2019, PloS one.

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT

M. Lux, M. Beckmann, L. Häberle, 2022, Geburtshilfe und Frauenheilkunde.

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.

M. Lux, M. Beckmann, P. Fasching, 2022, European journal of cancer.

Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1.

A. Schneeweiss, A. Trumpp, K. Pantel, 2023, Journal of proteome research.

Palliative Radiotherapy for Symptomatic Locally Advanced Breast Cancer

A. Schneeweiss, M. Wallwiener, J. Debus, 2023, Technology in cancer research & treatment.

Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

C. Denkert, F. Marmé, S. Loibl, 2021 .

CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer

S. Fröhling, A. Schneeweiss, D. Jäger, 2021, JCO precision oncology.

T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.

A. Schneeweiss, F. Marmé, J. L. Bermejo, 2015, Anticancer Research.

Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer

L. Uhlmann, A. Schneeweiss, M. Golatta, 2022, Archives of Gynecology and Obstetrics.

Relationship of Ki-67 index in biopsies of metastatic breast cancer tissue and circulating tumor cells (CTCs) at the time of biopsy collection.

A. Schneeweiss, K. Pantel, S. Riethdorf, 2023, Archives of gynecology and obstetrics.